Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Jul 17, 2020 10:48am
245 Views
Post# 31281016

Patience

Patience I am not pumping here nor am I here with knowledge .... I can only go by what they put in NR as my facts .... they have publicly attached other names such as Salzman and even scientists that have worked along side both parties ... with producing this R107 liquid injection NO ... this alone would be a law suit if it were not true ...so any idea about a lawsuit is nonsense to me.. since on board with Kly because of their GVHD drug... we still dont know the end result... do we keep it and get a NR later re funding ... but to date... while covid is now and possible future ... we do know that already that INO is being tested on humans for covid .... Kly just gave us a NR that we got the lisence and being proactive moving it forward...Kly indicated that phase 1 fully paid by Salzman (Barda assuming) ... and before we get unhalted Kly has to prove and provide working capital for 6 months to Iiroc ...they also indicated that they would apply for funding for phase 2 and 3 .... as an investor I take this news as positive ... as for too late with covid ... I honestly dont think so...because if results in gas form are great ... and if phase 1 in R107 to be completed 4th Q 2020 has great results ...and if you read through NR we may just be pushed ahead of the line...and INO has already been FDA approved for a good few years ... again as put by another investor patience ... I know patience is running thin but wait and see after PP and more NR ... if we get unhalted while the rest of paperwork re filings is being completed ... we all will get a better feeling good or bad where you stand .... glta
<< Previous
Bullboard Posts
Next >>